<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-85354</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Etiology and sensitivity of uropathogens identified in uncomplicated lower urinary tract infections in women (ARESC Study): implications on empiric therapy</dc:title>
<dc:description xml:lang="en">Background and objective: To determine the etiology and susceptibility of uropathogens identified in women with uncomplicated lower urinary tract infections (UTI). Patients and methods: In a multicenter study (ARESC) in 9 Spanish hospitals, 803 female patients with uncomplicated cystitis were consecutively enrolled and evaluated to identify the uropathogens and their susceptibility to 9 antimicrobials.Results: Of 803 patients with uncomplicated cystitis, 784 patients were included. A positive urine culture was found in 87.7% of the samples. Of the 650 pathogens isolated, Escherichia coli (E. coli) was the most frequent (79.2%) followed by Staphylococcus saprophyticus (4.4%), Proteus mirabilis (4.3%), Enterococcus faecalis (3.2%) and Klebsiella pneumoniae (2.3%). E. coli showed a high rate of susceptibility to phosphomycin (97.2%), nitrofurantoin (94.1%) and somewhat lower to ciprofloxacin (88.1%). Fluorquinolone resistance rates were higher among postmenopausal women (17 versus 10%). E. coli was highly resistant to ampicillin (65%) and cotrimoxazole (34%) and 25% of the strains were resistant to amoxicillin/clavulanalic acid and cefuroxime. Conclusions: In Spain, E. coli shows high resistance rates to widely used antimicrobial antibiotics. Phosphomycin and nitrofurantoin have a high in vitro activity. Taking into account practical aspects such as convenience (only one dose), and the influence of the amount of fluorquinolone use on enterobacteriaceae and other microorganisms resistance levels, phosphomycin trometamol represents the option of first choice for the empirical treatment of uncomplicated cystitis in women (AU)</dc:description>
<dc:creator>Molina, Israel</dc:creator>
<dc:creator>Ledesma, José Mª</dc:creator>
<dc:creator>Palou, Joan</dc:creator>
<dc:creator>Pigrau, Carles</dc:creator>
<dc:creator>Angulo, Javier</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Pacientes y método: Estudio multicéntrico ARESC de 9 hospitales españoles, que incluyó de forma consecutiva 803 mujeres, de edades entre 18 y 65 años, con cistitis no complicada, con el fin de identificar la etiología y evaluar su sensibilidad a 9 antimicrobianos. Resultados: De 803 pacientes consecutivas con ITU baja no complicada, fueron finalmente incluidas 784 pacientes. El urocultivo fue positivo en el 87,7% de las muestras. De un total de 650 uropatógenos, Escherichia coli (E. coli) fue el más frecuente (79,2%), seguido por Staphylococcus saprophyticus (4,4%), Proteus mirabilis (4,3%), Enterococcus faecalis (3,2%) y Klebsiella pneumoniae (2,3%). E. coli mostró una elevada sensibilidad a fosfomicina (97,2%), nitrofurantoína (94,1%) y algo menor a ciprofloxacino (88,1%). Las tasas de resistencia a fluorquinolonas fueron más elevadas en mujeres postmenopáusicas (17 frente a 10%). E. coli sigue presentando unas elevadas resistencias a ampicilina (65%) y a cotrimoxazol (34%), y en la actualidad, aproximadamente un 25% de las cepas son resistentes a amoxicilina/clavulánico y  cefuroxima. Conclusiones: En España se observan elevados índices de resistencia de E. coli a antibióticos de amplio uso. Fosfomicina y nitrofurantoína preservan una elevada actividad in vitro. Considerando otros aspectos prácticos, como la posología (una sola dosis) y la influencia del consumo total de quinolonas sobre los niveles de resistencia en enterobacterias y en otros microorganismos, fosfomicina trometamol representa una alternativa empírica de primera elección para la cistitis no complicada de la mujer (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);136(1): 1-7, ene. 2011. tab</dc:source>
<dc:identifier>ibc-85354</dc:identifier>
<dc:title xml:lang="es">Etiología y sensibilidad de los uropatógenos identificados en infecciones urinarias bajas no complicadas de la mujer (Estudio ARESC): implicaciones en la terapia empírica</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d5712^s22079</dc:subject>
<dc:subject>^d14952^s22046</dc:subject>
<dc:subject>^d24903^s22079</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22165</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3574^s22046</dc:subject>
<dc:subject>^d24244^s22074</dc:subject>
<dc:subject>^d36060^s22079</dc:subject>
<dc:subject>^d2547^s22079</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d9767^s22079</dc:subject>
<dc:subject>^d33384^s22079</dc:subject>
<dc:subject>^d2479^s22079</dc:subject>
<dc:type>article</dc:type>
<dc:date>201101</dc:date>
</metadata>
</record>
</ibecs-document>
